TPG's $2B Par Pharma Buyout Bid Harms Investors, Suit Says
A Par Pharmaceutical Cos. Inc. shareholder launched a class action Wednesday challenging private equity firm TPG Capital's $1.9 billion bid to take the generic-drug maker private, saying the deal was based...To view the full article, register now.
Already a subscriber? Click here to view full article